Real-World Comparative Effectiveness Study of TYVASO (Inhaled Treprostinil) in the Treatment of PH-ILD

ENCePP Code of conduct

Yes

Data sources

• Data source(s), other:
  - Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA Registry); - Registro Español de Hipertensión pulmonar Asociada a enfermedad Respiratoria (REHAR); - Royal Brompton Hospital National Pulmonary Hypertension Service Pulmonary Hypertension Registry; ; Clinical trial data from:; - Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE (RIN-PH-201, NCT02630316); - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE (RIN-PH-202, NCT02633293)
• Data sources (types):
  Clinical trial

  Disease registry

Use of a Common Data Model (CDM)

• CDM mapping:
  Yes

CDM Mappings

• CDM name (other):
  Real-World Comparative Effectiveness Study of TYVASO (Inhaled Treprostinil) in the Treatment of PH-ILD
• CDM version:
  In Progress

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  No
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Yes
• Data characterisation moment:
  after extract-transform-load to a common data model